Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route. These publications focused predominantly on healthcare resource utilization and economic outcomes, demonstrating resource and cost savings with sc. administration. Patients reported a better health-related quality of life and preference for sc. formulations. Time-and-motion study analyses confirmed the convenience of sc. administration. These findings suggest that future availability of sc. oncology biologics, especially anti-PD-1/PD-ligand 1 antibodies due to their increased utility in various malignancies, may be beneficial for patients, healthcare providers and payers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of this SLR are consistent with other published SLRs that have reported on the time, resource, and cost savings associated with SC administration versus IV, for both oncology and non-oncology biologics [123–125].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [123]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 298
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola, M., Sequeira, J., Seiça, R., Veiga, F., Serra, J., Santos, A. C., & Ribeiro, A. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.001 · Cited by 234
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177
Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154
Research works printed but not linked: 15
- Bacchiarri F , NozzoliC, AntonioliEet al. Safety and efficacy of SC versus IV bortezomib in patients with newly elderly diagnosed multiple myeloma. Haematologica102(Suppl. 3), 167 (2017).
- Calvache J , BricenoV. Budget impact analysis of the use of trastuzumab SC in the treatment of HER2 positive in public health institutions of Ecuador. Value Health20, A130 (2017).
- Castillo-Fernandez O , CabrejaA, ArauzEet al. Do patients and nurses outside clinical trial prefer SC trastuzumab over conventional IV infusion? Instituto Oncologico Nacional experience. Cancer Res.77(Suppl. 4), P5-11-16 (2017).
- Cocquyt VF , Martinez-MenaCL, MartensMTet al. BELIS: safety and tolerability of at home administration of trastuzumab (Herceptin) SC for the treatment of patients with HER2-positive early breast cancer. Cancer Res.77(4; Suppl. 1), P4-21-17 (2017).
- Di Rocco A , ScerboG, AnsuinelliMet al. Efficacy, safety and cost analysis of SC vs IV rituximab in patients with diffuse large B-cell lymphoma treated with RCHOP. Haematologica3, 110–111 (2017).
- Dumitru D , BensonJ, WishartGet al. Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS). Cancer Res.77(4 Suppl. 1), P1-11-03 (2017).
- Gomes G , HoR, RufinoCet al. Budget impact analysis of rituximab IV versus SC from public Brazilian hospital. ISPOR 22nd Annual International Meeting. Boston, MA (2017).
- Irwin S , RowntreeC, CoshHet al. Positive benefits of changing from IV rituximab administration to SC administration: a single centre experience. Br. J. Hematol.176(Suppl. 1), 68–69 (2017).
- Lopez MA , SamanesMA, TenaIPet al. Switching from IV to SC formulation of trastuzumab: costs and safety. Eur. J. Hosp. Pharm.24(Suppl. 1), A57 (2017).
- Martin C , AlcedoJ, AraúzE. Comparative analysis of costs between SC formulation of trastuzumab versus IV formulation from the perspective of the Instituto Oncológico Nacional of Panamá from January to December 2016. Cancer Res.78(Suppl.4), P4-12-13 (2018).
- Nierenberger A , GessierF, ForgesFet al. SC trastuzumab versus IV trastuzumab: an impact study. Eur. J. Hosp. Pharm.24, A216 (2017).
- Nikolov O , SterjevZ, DimovskiAet al. Cost-minimization analysis of rituximab SC formulation versus IV administration of rituximab for the treatment of non-Hodgkin’s lymphoma in the Republic of Macedonia. Haematologica102(Suppl. 2), 600 (2017).
- Petrakova K , MelicharB, BortlicekZet al. Preference of trastuzumab administration route (IV or SC) in patients in the Czech Republic. Cross-sectional study on 429 patients. Cancer Res.77(Suppl.4), P4-21-12 (2017).
- Stojanovik A , CvetanovskaL, ChevreskaLet al. Preference of Macedonian NHL patients for SC vs IV administration of rituximab. Leukemia Res.61, S32 (2017).
- Tomarchio V , SuranoMA, TafuriMAet al. Management, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies. Haematologica102, 298 (2017).
Cited by
Mateos, M.-V., Nahi, H., Legiec, W., Grosicki, S., Vorobyev, V., Spicka, I., Hungria, V., Korenkova, S., Bahlis, N., Flogegard, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30070-3 · Cited by 254
Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00166-2 · Cited by 171
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Subcutaneous drug delivery from nanoscale systems
Tomasini, L., Ferrere, M., & Nicolas, J. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00161-w · Cited by 71
“It also reduces the financial burden of treatment 23 , which is a key point for payers.”
InfluentialBurotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S. N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.009 · Cited by 56
Metadata
- Authors
- Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A.
- Affiliations
- Harvard University (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Alabama at Birmingham (US)
- Pfizer (United States) (US)
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2019-08-09
- Volume
- 15
- Issue
- 28
- Pages
- 3267-3281
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2966881177
- Cited by
- 69
- References
- 71
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 5 · 2021: 10 · 2020: 7
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Food and Drug Administration
- Leukemia and Lymphoma Society
- Multiple Myeloma Research Foundation
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- subcutaneous administration, intravenous administration, route of administration, healthcare resource utilization, cost reduction, health-related quality of life, patient preferences, time and motion study, anti-PD-1/PD-L1 antibodies
- MeSH terms
- Antineoplastic Agents, Biological Products, Cost-Benefit Analysis, Humans, Injections, Subcutaneous, Neoplasms, Prognosis, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics. https://app.cochat.ai/papers/10.2217/fon-2019-0368
- The paper
- Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019). Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics. Future Oncology. https://doi.org/10.2217/fon-2019-0368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.